Skip to main content

Oncology Advances

Featured Content |Content Library

Study Reveals Factor That Determines ‘Fate’ of Cancer Cells When Tumor Suppressor Gene Function is Restored News

Study Reveals Factor That Determines ‘Fate’ of Cancer Cells When Tumor Suppressor Gene Function is Restored

Many cancers develop from cells that have a malfunctioning tumor suppressor gene, p53, which normally helps control unchecked cell growth and prevent cancer.

“45 is the New 50” as Age for Colorectal Cancer Screening is Lowered News

“45 is the New 50” as Age for Colorectal Cancer Screening is Lowered

Prompted by a recent alarming rise in cases of colorectal cancer in people younger than 50, an independent expert panel has recommended that individuals of average risk for the disease begin screening exams at 45 years of age instead of the traditional 50.

COVID-19 Vaccine Study in Cancer Patients Video

COVID-19 Vaccine Study in Cancer Patients

Dana-Farber researchers are leading a study that looks at the effects of the COVID-19 vaccine in cancer patients.

New ‘Druggable’ Genetic Targets Identified in Rare Type of Bile Duct Cancer News

New ‘Druggable’ Genetic Targets Identified in Rare Type of Bile Duct Cancer

Scientists are beginning to make inroads into treating cholangiocarcinoma, a rare, lethal cancer of the bile ducts, with precision drugs. Last year, the first targeted drug for some patients with the disease was approved.

Study Finds Lower Mortality Rate for Men at High Risk for Death from Prostate Cancer Who Received Early Postoperative Radiation Therapy News

Study Finds Lower Mortality Rate for Men at High Risk for Death from Prostate Cancer Who Received Early Postoperative Radiation Therapy

In a large, international retrospective study, men at high risk for death from prostate cancer had a significant reduction in all-cause mortality if treated with radiation shortly after surgery

Dana-Farber Scientists Work to Accelerate Development for Blood Tests for Ovarian Cancer News

Dana-Farber Scientists Work to Accelerate Development for Blood Tests for Ovarian Cancer

A new partnership between researchers at Dana-Farber Cancer Institute and University College London (UCL) may prove decisive in the quest to develop the first blood test for early-stage ovarian cancer.